|
A potentially more important Phase 2 clinical of Fulvestrant+ Herceptin is running since April 2006 under Dr Pietras. It is unfortunately going slow due to low enrolment of patients.
If the theory backing the trial is confirmed it would prove that Fulvestrant in suppressing the estrogen receptors (without affecting estrogen) prevents interaction between the ER & HER-2 which is said to occur at least in some cases when Herceptin treatment leads to activation of the ER pathway independantly of circulating estrogen.
Last edited by heblaj01; 12-16-2006 at 06:57 AM..
Reason: omited phase 2
|
Hybrid Mode
